Evaluation of human immunodeficiency virus seroprevalence in population surveys using pooled sera.
The pooling of individual serum samples to determine human immunodeficiency virus (HIV) seropositivity was examined to assess whether testing pooled sera was technically feasible, cost-effective, and accurate for estimating seroprevalence in large population surveys. The sensitivities and specificities of three commercially available HIV enzyme-linked immunosorbent assay (ELISA) kits were tested using 65 serum pools of 15 individual serum samples each (975 total serum samples) at two different dilutions. With pooled sera, the Organon Teknika Bio-EnzaBead ELISA at half the dilution recommended by the manufacturer showed the best agreement with ELISA and Western blot results of individual sera. In subsequently testing 92 pools, each containing 15 individual serum samples from a population of American patients attending a sexually transmitted diseases clinic, the estimated seroprevalence was 5.27 compared with 4.93% in a test of 1,380 individual serum samples and 5.19% in a test of 4,028 individual serum samples from the same population. In an evaluation of 1,380 African patients using 10 serum samples per pool, the estimated seroprevalence was 5.79 compared with 6.16% in a test of individual sera. These results indicate that ELISA testing with pooled sera is highly sensitive and specific and appears to be a cost-effective means for estimating HIV seroprevalence in large population-based surveys.
National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.
R L
RL
Kline
T A
TA
Brothers
R
R
Brookmeyer
S
S
Zeger
T C
TC
Quinn
D015142:Baltimore; D015153:Blotting, Western; D015023:Democratic Republic of the Congo; D004797:Enzyme-Linked Immunosorbent Assay; D006678:HIV / Q000302:isolation & purification*; D006679:HIV Seropositivity / Q000453:epidemiology*; D006801:Humans; D011237:Predictive Value of Tests; D013048:Specimen Handling